CoChat

Current Studies of Liposome Muramyl Tripeptide (CGP 19835A Lipid) Therapy for Metastasis in Spontaneous Tumors: A Progress Review*

Macewen, E. G., Kurzman, I. D., Helfand, S., Vail, D., London, C., Kisseberth, W., Rosenthal, R. C., Fox, L. E., Keller, E. T., Obradovich, J., Madewell, B., Rodriguez, C., Kitchell, B., Fidel, J., Susaneck, S., Rosenberg, M. · 1994 · Journal of Drug Targeting
Cited by 40

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Targeted delivery of macrophage activating agents is an attractive approach to treat micrometastatic disease. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) is a potent activator of monocytes/macrophages in humans, mice, and dogs. We have conducted clinical trials in dogs with malignant and highly metastatic spontaneous tumors. Presented are results of our trials evaluating L-MTP-PE in combination with surgery and chemotherapy in dogs with spontaneous osteosarcoma and hemangiosarcoma, particularly relevant malignancies having having many similarities to human cancer. Osteosarcoma dogs received chemotherapy following surgery (cisplatin q 28 days x 4). At completion of chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.021). Dogs with splenic hemangiosarcoma received combination chemotherapy following surgery (doxorubicin and cyclophosphamide q 21 days x 4). At the first chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.03). These studies show that L-MTP-PE is an effective agent for treatment of metastasis and can be safely administered in combination with chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/10611869408996814

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 40

Metadata

Authors
Macewen, E. G., Kurzman, I. D., Helfand, S., Vail, D., London, C., Kisseberth, W., Rosenthal, R. C., Fox, L. E., Keller, E. T., Obradovich, J., Madewell, B., Rodriguez, C., Kitchell, B., Fidel, J., Susaneck, S., & Rosenberg, M.
Venue
Journal of Drug Targeting
Published
1994-01
Volume
2
Issue
5
Pages
391-396
ISSN
  • 1026-7158 (ISSN-L)
  • 1061-186X
  • 1029-2330
OpenAlex
W2130747898
Cited by
40
References
1
FWCI
2.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current Studies of Liposome Muramyl Tripeptide (CGP 19835A Lipid) Therapy for Metastasis in Spontaneous Tumors: A Progress Review*. https://app.cochat.ai/papers/10.3109/10611869408996814
The paper
Macewen, E. G., Kurzman, I. D., Helfand, S., Vail, D., London, C., Kisseberth, W., Rosenthal, R. C., Fox, L. E., Keller, E. T., Obradovich, J., Madewell, B., Rodriguez, C., Kitchell, B., Fidel, J., Susaneck, S., & Rosenberg, M. (1994). Current Studies of Liposome Muramyl Tripeptide (CGP 19835A Lipid) Therapy for Metastasis in Spontaneous Tumors: A Progress Review*. Journal of Drug Targeting. https://doi.org/10.3109/10611869408996814

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.